Provide any other advice or information for the GP and district nursing,hospital teams or hospice teams if required.Provide clear advice for the prescribing of octreotide and any syringe driveruse. Stop the treatment when no longer considered to be appropriate.6.0 GP ResponsibilitiesOnce stable and SCP agreed, prescribe octreotide and arrange ongoingmonitoring of symptoms and site reaction as advised and agreed with thespecialist.Issue appropriate prescriptions for up to 2 weeks duration.Refer to specialist when symptoms fail to respond or if stable and symptomcontrolled but suspicion of ADR (eg gallstones or erratic TFTs)Review the patient at regular agreed intervals to monitor control of symptoms. Identify adverse drug reactions and report to Specialist and CSM.Liaise with community and specialist nurses as needed regarding ongoingpatient care. This document will be reviewed in the light of new or emerging evidence or by May 2021
Doncaster & Bassetlaw Area Prescribing Committee Approved May 2016 V2.07.0 District nursing team/community specialist palliative care nurses/wardnursing teams/hospital specialist palliative care nurses responsibilities Should ensure that they have this advice and an understanding of thesubcutaneous route of octreotide medication when admitting thepatient/completing a care plan or first assessment and reviews.Understand the time that it may take to obtain octreotide in the community andwork with the team and the patient to plan that the medication does not runout.Be aware of the potential side effects and beneficial effects of octreotide fromthis advice.Have the contact details for the GP and consultants in palliative medicine inthe patients care plan and understand who to contact if problems.Follow the usual policies for syringe drivers, ’Instruction to Administer’ andcare plans as for any syringe driver or subcutaneous medications prescribedas per policy within the organisation in which the nursing staff are employed.This information is not inclusive of all prescribing information and potentialadverse effects. Please refer to the full prescribing data SPC, the BNF and thecurrent Palliative Care Formulary. Information is also available atThe Consultants in Palliative Medicine are available during working hoursthrough their secretaries and out of hours there is a consultant in Palliativemedicine available through DRI switchboard.8.0 Guidance DevelopmentReferencePalliative Care Formulary third edition (PCF3), R Twycross, A Wilcock, palliativedrugs.com Ltd. 2008. Written By: Dr L. McTague, Consultant in Palliative CareDr A. Carey, Consultant in Palliative CareDr M Fernando, Consultant in Palliative CareReviewed by:NHS Doncaster and Bassetlaw APCJan 2012Reviewed by:DBHFTMay 2016Approved by:NHS Doncaster and Bassetlaw APCMay 2016This document will be reviewed in the light of new or emerging evidence or by May 2021
You've reached the end of your free preview.
Want to read all 5 pages?
- Fall '16
- Jeff Miller